NCT02629120 is a Phase 1, PHASE2 clinical trial of Alemtuzumab in Chronic Granulomatous Disease Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT02629120?

NCT02629120 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT02629120?

Interventions in NCT02629120: Alemtuzumab, Busulfan, Sirolimus, Cyclophosphamide, Total Body Irradiation, Peripheral blood stem cells.

What condition does NCT02629120 study?

NCT02629120 studies Chronic Granulomatous Disease Transplant.

Is NCT02629120 still recruiting?

NCT02629120 is currently active, enrolled. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT02629120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Active, enrolled Phase 1, PHASE2 Last updated 1 April 2026

What this trial tests

Phase 1, PHASE2 trial testing Alemtuzumab in Chronic Granulomatous Disease Transplant in 45 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 December 2015

Primary endpoint
30 December 2027

30 December 2028

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	17 December 2015
Primary completion	30 December 2027
Estimated completion	30 December 2028
Sites	1 location across United States

Drugs / interventions tested

Alemtuzumab (ALEMTUZUMAB) — full drug profile →
Busulfan — full drug profile →
Sirolimus (sirolimus) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Total Body Irradiation
Peripheral blood stem cells

Conditions studied

Chronic Granulomatous Disease Transplant — all drugs for Chronic Granulomatous Disease Transplant →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 4 to 65, any sex, with Chronic Granulomatous Disease Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic granulomatous disease (CGD) affects white blood cell function. Currently, the only curative treatment is bone marrow transplant to replace the abnormal stem cells with new ones (donor cells) capable of making a normal immune system. Transplant problems include graft versus host disease (GvHD) and graft rejection. With GvHD, donor cells attack the recipient s normal tissue. Researchers want to use preparation drugs and a high cell dose to increase graft success. They want to use 2 immunosuppressive drugs (cyclophosphamide and sirolimus) to lessen the risk of GvHD. ...

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Williams L, Cirrone F, Cole K, Abdul-Hay M, et al · · 2020 · cited 32× · PMID 32373119 · DOI 10.3389/fimmu.2020.00636
Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease.
Kline A, Parta M, Cuellar-Rodriguez J, Gea-Banacloche J, et al · · 2025 · cited 3× · PMID 39496936 · DOI 10.1038/s41409-024-02389-x
Febrile neutropenia management and outcomes in hematopoietic cell transplantation for chronic granulomatous disease.
Parta M, Cuellar-Rodriguez J, Gea-Banacloche J, Qin J, et al · · 2022 · cited 1× · PMID 35191140 · DOI 10.1111/tid.13815

Verify or expand the search:

Other trials of Alemtuzumab

Trials testing the same drug.

NCT06959771 — Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study · Phase 1, PHASE2 · recruiting
NCT06872333 — Allo HSCT for High Risk Hemoglobinopathies · Phase 2 · recruiting
NCT05501756 — Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation · Phase 2 · recruiting
NCT05384756 — TMLI and Alemtuzumab for Treatment of Sickle Cell Disease · Phase 1 · active not recruiting
NCT06310343 — ADAs to Alemtuzumab · completed

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02629120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02629120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing